Drug Innovation and Longevity

Ivor O’Shea FSAI, FIA 

4 June 2019 Presented by webinar: Tuesday 4 June 2019 at 11.30

Introduction • Drug innovation is central to longevity gains for many diseases – Includes infectious diseases (vaccines & antibiotics) and cardiovascular diseases (statins) – Clinical trials for many drugs have demonstrated longevity gains so causality is present • Conversely, Alzheimer’s shows what happens when drug innovation is absent • USA is central to any analysis of drug innovation – 1/3 of world pharma sales and 1/2 of world pharma profits • This presentation will analyse key drug innovation in the US pharma market to – Show its broad impact on longevity trends in recent decades – Develop some thoughts on likely longevity impact over the next 20-30 years • This presentation does not seek to quantify in mathematical terms the correlation/causality between drug innovation and longevity